{
  "trial_id": "NCT02710812",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Major or complete clinical response at restaging after 7-8 weeks from the end of neoadjuvant therapy, confirmed at second restaging (after 11-12 weeks from the end of neoadjuvant therapy)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Written informed consent (after 2nd restaging)",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "palpable mass on digital rectal examination",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "deep ulcer with surface > 2 cm in diameter or obvious signs of endoscopic residual disease",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "presence of metastatic lymph nodes at MRI (> 5 mm along short axis)",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has pancreatic adenocarcinoma and a diverticular abscess. She was treated with IV antibiotics.",
  "_meta": {
    "topic_id": "15",
    "trial_id": "NCT02710812",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}